UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 2035-12
Program Prior Authorization/Medical Necessity – Topical Antifungals
Medication Jublia® (efinaconazole) and tavaborole
P&T Approval Date 11/2014, 4/2015, 4/2016, 4/2017, 4/2018, 4/2019, 4/2020, 4/2021,
4/2022, 10/2023, 10/2024
Effective Date 1/1/2025
1. Background:
Jublia (efinaconazole) and tavaborole are both indicated for the treatment of onychomycosis due to
Trichophyton rubrum and Trichophyton mentagrophytes. Presence of these organisms may be
determined using molecular diagnostic testing. Fungal cultures require a longer turnaround time to
obtain diagnosis.
2. Coverage Criteriaa:
A. Jublia or tavaborole will be approved based on all of the following criteria:
1. Submission of medical records (laboratory and clinical documentation) confirming
diagnosis of onychomycosis of the toenail with of one of the following infections (if
request is for a subsequent course of therapy a new test must be performed):
a. Trichophyton rubrum
b. Trichophyton mentagrophytes
-AND-
2. Treatment is requested due to medical condition and not for cosmetic purposes (e.g.,
patients with history of cellulitis of the lower extremity who have ipsilateral toenail
onychomycosis, patients with diabetes who have additional risk factors for cellulitis,
patients who experience pain/discomfort associated with the infected nail)
-AND-
3. History of failure after a minimum of 12 weeks of treatmentb, contraindication, or
intolerance to two of the following antifungal agents (please document date of trial):
a. itraconazole (generic Sporanox)
b. oral terbinafine (generic Lamisil)
c. ciclopirox (generic Penlac)
Authorization will be issued for 48 weeks.
© 2024 UnitedHealthcare Services Inc.
1
a. State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
b For Connecticut, Kentucky and Mississippi business, only a 30 day trial will be required.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Jublia [Package Insert]. Bridgewater, NJ: Bausch Health Companies Inc.; March 2022.
2. Tavaborole [Package Insert]. bedminster, NJ: Alembic Pharmaceuticals, Inc.; December
2023.
3. Treating Onychomycosis. Am Fam Physician. 2001 Feb 15;63(4):663-72, 677-8.
4. Goldstein AO. Onychomycosis: Management. UpToDate. September 2022. Accessed
September 5, 2024.
5. Grag J, Tilak R, Sanjay S, et al. Evaluation of Pan-Dermatophyte Nested PCR in Diagnosis
of Onychomycosis. 2007. J Clin Microbiology. 45:3443-3445.
Program Prior Authorization/Medical Necessity – Topical Antifungals
Change Control
Date Change
11/2014 New program
4/2015 Revised first line drugs to trial of 2 of 3 with addition of ciclopirox.
4/2016 Removed specified testing requirements. Added requirement for
diagnosis of Trichophyton rubrum or Trichophyton mentagrophytes.
Added minimum treatment durations to step 1 agents.
7/2016 Added Indiana and West Virginia coverage information.
4/2017 Updated references. State mandate reference language updated.
4/2018 Annual review. Updated references.
4/2019 Annual review. Revised documentation requirements. Updated
references.
4/2020 Annual review. Updated references.
4/2021 Annual review. Administrative change for reformatting and clarity.
Updated references.
4/2022 Annual review. Corrected spelling of ciclopirox. State mandate
reference language updated. Updated references.
10/2023 Annual review. Noted brand Kerydin is typically excluded. Updated
references.
© 2024 UnitedHealthcare Services Inc.
2
10/2024 Removed references to brand Kerydin as it is no longer on the market.
Updated CT/KY/MS state mandate footnote. Updated references.
© 2024 UnitedHealthcare Services Inc.
3